Elanco Animal Health Inc (NYSE: ELAN)’s stock price has gone decline by -2.00 in comparison to its previous close of 13.53, however, the company has experienced a -2.28% decrease in its stock price over the last five trading days. Zacks Investment Research reported 2024-05-06 that Beyond analysts’ top -and-bottom-line estimates for Elanco Animal Health (ELAN), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2024.
Is It Worth Investing in Elanco Animal Health Inc (NYSE: ELAN) Right Now?
Moreover, the 36-month beta value for ELAN is 1.39. Analysts have varying opinions on the stock, with 4 analysts rating it as a “buy,” 1 as “overweight,” 6 as “hold,” and 0 as “sell.”
The public float for ELAN is 489.28M and currently, short sellers hold a 3.17% of that float. On May 07, 2024, ELAN’s average trading volume was 4.15M shares.
ELAN’s Market Performance
ELAN stock saw a decrease of -2.28% in the past week, with a monthly decline of -14.78% and a quarterly a decrease of -16.60%. The volatility ratio for the week is 3.07%, and the volatility levels for the last 30 days are 3.52% for Elanco Animal Health Inc (ELAN). The simple moving average for the last 20 days is -3.54% for ELAN’s stock, with a simple moving average of 1.08% for the last 200 days.
Analysts’ Opinion of ELAN
Many brokerage firms have already submitted their reports for ELAN stocks, with Stifel repeating the rating for ELAN by listing it as a “Buy.” The predicted price for ELAN in the upcoming period, according to Stifel is $20 based on the research report published on January 05, 2024 of the current year 2024.
Jefferies, on the other hand, stated in their research note that they expect to see ELAN reach a price target of $17. The rating they have provided for ELAN stocks is “Buy” according to the report published on December 19th, 2023.
Morgan Stanley gave a rating of “Overweight” to ELAN, setting the target price at $16 in the report published on December 15th of the previous year.
ELAN Trading at -12.07% from the 50-Day Moving Average
After a stumble in the market that brought ELAN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -21.45% of loss for the given period.
Volatility was left at 3.52%, however, over the last 30 days, the volatility rate increased by 3.07%, as shares sank -14.34% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -19.00% lower at present.
During the last 5 trading sessions, ELAN fell by -2.28%, which changed the moving average for the period of 200-days by +14.61% in comparison to the 20-day moving average, which settled at $13.64. In addition, Elanco Animal Health Inc saw -11.01% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ELAN starting from DOYLE WILLIAM F, who purchase 15,000 shares at the price of $16.30 back on Mar 08 ’24. After this action, DOYLE WILLIAM F now owns 61,330 shares of Elanco Animal Health Inc, valued at $244,500 using the latest closing price.
Harrington Michael J, the Director of Elanco Animal Health Inc, purchase 3,100 shares at $16.29 during a trade that took place back on Mar 08 ’24, which means that Harrington Michael J is holding 77,594 shares at $50,494 based on the most recent closing price.
Stock Fundamentals for ELAN
Current profitability levels for the company are sitting at:
- 0.06 for the present operating margin
- 0.56 for the gross margin
The net margin for Elanco Animal Health Inc stands at -0.28. The total capital return value is set at 0.02. Equity return is now at value -18.22, with -8.25 for asset returns.
Based on Elanco Animal Health Inc (ELAN), the company’s capital structure generated 0.48 points at debt to capital in total, while cash flow to debt ratio is standing at 0.05. The debt to equity ratio resting at 0.93. The interest coverage ratio of the stock is 1.02.
Currently, EBITDA for the company is 945.0 million with net debt to EBITDA at 6.52. When we switch over and look at the enterprise to sales, we see a ratio of 2.71. The receivables turnover for the company is 4.37for trailing twelve months and the total asset turnover is 0.31. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.75.
Conclusion
To wrap up, the performance of Elanco Animal Health Inc (ELAN) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
